-
REAL-WORLD CONCORDANCE WITH THE FRAMINGHAM STROKE RISK MODEL IN ATRIAL FIBRILLATION AND IDENTIFICATION OF ADDITIONAL SIGNIFICANT FEATURES
Mar 18, 2026, 21:38 PM -
DEVELOPMENT OF A MULTI-AGENT "DEEP" AI SYSTEM FOR HEOR EVIDENCE AND INTELLIGENCE GENERATION
Mar 18, 2026, 21:38 PM -
HETEROGENEOUS RESPONSES TO BRAZIL’S PHARMACEUTICAL PRICE CAP REGULATION: EVIDENCE FROM PRIVATE INSURANCES AND THE UNIFIED HEALTH SYSTEM
Mar 18, 2026, 21:38 PM -
PATTERNS AND PREDICTORS OF LUNG CANCER CARE TRAJECTORIES: A SEQUENCE ANALYSIS OF INSURANCE CLAIMS
Mar 18, 2026, 21:38 PM -
GLOBAL AVAILABILITY AND ACCESS TO EVIDENCE-BASED ANTI-OBESITY PHARMACOTHERAPIES: A SYSTEMATIC ASSESSMENT OF REGULATORY AND REIMBURSEMENT LANDSCAPES
Mar 18, 2026, 21:38 PM -
THE TOTAL COST OF CARE AND BUDGET IMPACT OF INTRODUCING MOSUNETUZUMAB PLUS POLATUZUMAB VEDOTIN FOR SECOND-LINE OR LATER (2L+) TREATMENT OF RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA (LBCL) TO A UNITED STATES (US) HEALTH PLAN
Mar 18, 2026, 21:38 PM -
UPDATED COST-EFFECTIVENESS ANALYSIS OF POLATUZUMAB VEDOTIN COMBINED WITH CHEMOIMMUNOTHERAPY FOR UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) IN CHINA: EVIDENCE FROM LONG-TERM FOLLOW-UP OF THE POLARIX ASIAN SUBGROUP
Mar 18, 2026, 21:38 PM -
THE DIABETES PENALTY, ARE WE COMPARING LIKE VERSUS LIKE IN OBESITY MANAGEMENT? RE-RANKING SEMAGLUTIDE AND TIRZEPATIDE AFTER ADJUSTING FOR COMORBID T2D CONFOUNDING
Mar 18, 2026, 21:38 PM -
DIGITAL CAREGIVER TRAINING FOR PROMOTING FUNCTIONAL INDEPENDENCE AND HEALTHY AGING
Mar 18, 2026, 21:38 PM -
TERMINAL CARE COSTS IN JAPAN USING LINKED HEALTH AND LONG-TERM CARE CLAIMS: WHICH IS MORE EXPENSIVE—HOSPITAL DEATH OR LONG-TERM CARE FACILITY DEATH?
Mar 18, 2026, 21:38 PM -
SIX MONTH OUTCOMES AND GLUCAGON-LIKE PEPTIDE-1 (GLP-1) THERAPY PERSISTENCE AMONG COMMERCIALLY INSURED ADULTS WITHOUT DIABETES IN AN OBESITY CARE MANAGEMENT PROGRAM
Mar 18, 2026, 21:38 PM -
DEVELOPING AND OPERATIONALIZING A SOCIETAL VALUE FRAMEWORK: A STYLIZED CASE STUDY IN ADVANCED HEPATOCELLULAR CARCINOMA
Mar 18, 2026, 21:38 PM -
FAST-TRACKING RARE DISEASES: USE OF FDA EXPEDITED PATHWAYS FOR ORPHAN DRUGS
Mar 18, 2026, 21:38 PM -
A NOVEL BAYESIAN MODELING APPROACH INCREASES PRECISION OF PREDICTED LONG-TERM DURABILITY OF ETRANACOGENE DEZAPARVOVEC FOR THE TREATMENT OF HEMOPHILIA B
Mar 18, 2026, 21:38 PM -
COST EFFECTIVENESS ANALYSIS OF ADULT PNEUMOCOCCAL VACCINES INCLUDING PCV21 AND PCV20 TO OPTIMIZE NATIONAL IMMUNIZATION PROGRAM IN JAPAN
Mar 18, 2026, 21:38 PM -
STANDARDIZING AN ANNUAL REFERENCE COMPARATOR OF HEALTHCARE UTILIZATION OF PAINFUL DIABETIC NEUROPATHY (PDPN): A U.S. CLAIMS COHORT META-ANALYSIS FOR MODELING AND PAYER BENCHMARKING
Mar 18, 2026, 21:38 PM -
CAREGIVER-DEFINED UNMET NEEDS TO SUPPORT PATIENT-CENTERED TRIAL DESIGN AND VALUE CONSIDERATIONS IN MULTIPLE SULFATASE DEFICIENCY (MSD)
Mar 18, 2026, 21:38 PM -
PRICE ANALYSIS OF GENE THERAPIES AUTHORIZED BY THE U.S. FOOD AND DRUG ADMINISTRATION
Mar 18, 2026, 21:38 PM -
TRENDS IN BACK PAIN HEALTHCARE UTILIZATION AND EXPENDITURES AMONG U.S. ADULTS: 2007 VS 2023
Mar 18, 2026, 21:38 PM -
INCREASED HEALTHCARE COSTS AND RESOURCE UTILIZATION FOLLOWING PROGRESSION IN PATIENTS WITH HR+/HER2- METASTATIC BREAST CANCER RECEIVING CHEMOTHERAPY
Mar 18, 2026, 21:38 PM
